APHTON CORP
10-Q, EX-27, 2000-06-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: APHTON CORP, 10-Q, 2000-06-14
Next: FIFTH THIRD FUNDS, 485APOS, 2000-06-14



<TABLE> <S> <C>




<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial  information  extracted from the Annual
Report on Form 10-K for the year ended January 31, 2000 and the Quarterly Report
on Form  10-Q for the  quarter  and three  months  ended  April 30,  2000 and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<CIK>                         0000840319
<NAME>                        Aphton Corporation
<MULTIPLIER>                                                       1,000

<S>                                                                 <C>
<PERIOD-TYPE>                                                      3-MOS
<FISCAL-YEAR-END>                                            JAN-31-2000
<PERIOD-START>                                                FEB-1-2000
<PERIOD-END>                                                 APR-30-2000
<CASH>                                                            13,817
<SECURITIES>                                                      17,640
<RECEIVABLES>                                                      8,152
<ALLOWANCES>                                                           0
<INVENTORY>                                                            0
<CURRENT-ASSETS>                                                  32,127
<PP&E>                                                             1,025
<DEPRECIATION>                                                      (865)
<TOTAL-ASSETS>                                                    40,438
<CURRENT-LIABILITIES>                                             (6,122)
<BONDS>                                                                0
                                                  0
                                                            0
<COMMON>                                                             (16)
<OTHER-SE>                                                       (80,490)
<TOTAL-LIABILITY-AND-EQUITY>                                     (40,438)
<SALES>                                                                0
<TOTAL-REVENUES>                                                     330
<CGS>                                                                  0
<TOTAL-COSTS>                                                          0
<OTHER-EXPENSES>                                                   3,490
<LOSS-PROVISION>                                                       0
<INTEREST-EXPENSE>                                                     0
<INCOME-PRETAX>                                                   (3,238)
<INCOME-TAX>                                                           0
<INCOME-CONTINUING>                                               (3,238)
<DISCONTINUED>                                                         0
<EXTRAORDINARY>                                                        0
<CHANGES>                                                              0
<NET-INCOME>                                                      (3,238)
<EPS-BASIC>                                                        (0.20)
<EPS-DILUTED>                                                      (0.20)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission